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Abstract. Sclerotium rolfsii lectin (SRL) is a lectin isolated 
from the fungus Sclerotium rolfsii and has exquisite binding 
specificity towards the oncofetal Thomsen-Friedenreich 
antigen (TF-Ag; Galβ1-3GalNAcα-O-Ser/Thr) and its 
derivatives. Previous studies have shown that SRL inhibits the 
proliferation of human colon, breast and ovarian cancer cells 
in vitro and suppresses tumour growth in mice when intro-
duced intratumourally. The present study assessed the effect of 
SRL on tumour growth when introduced intraperitoneally in 
BALB/c nude mice and investigated the pharmacokinetics and 
biodistribution of SRL in Swiss albino mice. When 9 doses 
of SRL (30 mg/kg body weight/mice) was administered to 
BALB/c nude mice bearing human colon cancer HT-29 xeno-
grafts, a substantial reduction in tumour size was observed. 
A 35.8% reduction in tumour size was noted in the treated 
animals after 17 days. SRL treatment also inhibited angiogen-
esis, and the tumours from the treated animals were observed 
to carry fewer blood vessels and express less angiogenesis 
marker protein CD31, than that from the control animals. 
Pharmacokinetics and biodistribution analysis revealed that 
SRL was detected in the serum after 1 h and its level peaked 
after 24 h. SRL was not detected in any of the organs apart 
from the kidney where a trace amount was detected after 24 h 
of SRL injection. No significant changes were observed in any 
of the biochemical parameters tested including SGOT, SGPT, 
LDH, CREAT and BUN in the SRL-treated mice compared to 
these levels in the controls. This suggests that SRL has good 
potential to be developed as a therapeutic agent for cancer 
treatment and warrant further investigations in vivo and subse-
quent clinical trials.
Introduction
Cancer is one of the major life threatening diseases world-
wide (1). Colorectal cancer is the third leading cause of 
cancer-associated mortality in both men and women in the 
world (2). Regular screening increases the likelihood that 
colorectal cancer is detected at an early stage, more likely to 
be cured and with faster recovery (3). Although significant 
progress has been made over the past few decades, effective 
treatment of this disease is still lacking. It is believed that 
targeted therapy that focuses on specific molecules or signal-
ling pathways hold the key for more effective treatment of this 
disease than the currently used chemotherapy.
Lectins, a group of highly diverse proteins of non-immune 
origin that are ubiquitous in nature, recognize specific carbo-
hydrate structures. Tumour cells in general display different 
carbohydrate profiles on the cell surface compared to non-
transformed cells which can be detected using lectins. Lectins 
can reasonably differentiate malignant tumours from normal 
cells, and hence are used for cancer diagnosis and some are also 
being studied for their possible use as therapeutic agents (4). 
Lectins from edible mushrooms, such as Agaricus bisporus, 
Agrocybe aegerita I & II, Kurkowa lectin Pleurotuseous, 
Tricholomamongolicum and Pholiotaadiposa, have been 
shown to exert antiproliferative effects in cancer in vitro and 
antitumor effects in vivo (5-11). The two main properties of 
lectins that is, selectivity and cytotoxicity, have been exploited 
for devising therapeutic strategies against cancer.
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Sclerotium rolfsii, lectin (SRL) purified from the fungus 
Sclerotium rolfsii (12) has been shown to have exquisite 
binding specificity toward Thomsen-Friedenreich antigen 
(TF-Ag; Galβ1-3GalNAcα-O-Ser/Thr) and its derivatives (13). 
The TF antigen is highly expressed by >90% of tumours and 
rarely occurs in normal tissues (14). The crystal structure of 
SRL determined at 1.1 Å resolution, revealed two carbohydrate 
binding sites (15). Our previous studies have shown that SRL 
binds specifically to human cancerous colon but not to normal 
colon and exhibits strong antiproliferative activity in human 
colon cancer (HT29 and DLD1) (16), breast cancer (mCF-7 
and ZR-75) and ovarian cancer (PA-1) cells by inducing 
cellular apoptosis (17,18). Recently, we demonstrated that the 
presence of SRL affects multiple cell signalling pathways with 
early effects on mAPK- and c-jUN-associated cell prolifera-
tion pathways followed by miRNA-associated cell activity and 
apoptosis pathways. Lectin affinity purification has extracted 
a total of 25 proteins in HT29 cells, including keratins, heat 
shock proteins HSP-60 and HSP-90, ATP synthase subunit α, 
mitochondrial retinal dehydrogenase 1, actin cytoplasmin 2, 
tubulins, pyruvate kinase-m, Annexin A2, peroxiredoxin-1, 
prohibitin, α-enolase and ADP/ATP translocase 2 that 
are known to be involved in cell survival, apoptosis and 
tumorigenesis (19,20). These effects of SRL together with 
its exquisite binding specificity towards TF-Ag-associated 
glycans prompted us to investigate the possibility of devel-
oping SRL as a therapeutic agent.
Materials and methods
Materials. Protease Inhibitor Cocktail Set III was obtained 
from Calbiochem (Darmstadt, Germany); CD-31 (PECAm-1) 
was obtained from Invitrogen (Carlsbad, CA, USA) and 
Dulbecco's modified Eagle's medium (DMEM) and fetal calf 
serum (FCS) were obtained from Gibco-Invitrogen (Paisley, 
UK). Bovine serum albumin (BSA), streptavidin-horseradish 
peroxidase, 3,3',5,5'-tetramethylbenzidine (TmB) and poly-L-
lysine solution were obtained from Sigma-Aldrich (St. Louis, 
mO, USA). Taq DNA polymerase was obtained from Invitrogen. 
Oligonucleotide primers and Tris buffer were obtained from 
Sigma-Aldrich and dNTPs from Fermentas (Waltham, mA, 
USA). 3-3'-Diaminobenzidine chromogen/H2O2 substrate in 
buffer solution (pH 7.5) (DAB kit) and rabbit anti-SRL poly-
clonal antisera were obtained from Bangalore Genei India 
Pvt. Ltd. (Bangalore India). Caspase-3 (3G2) mouse mAb was 
procured from Cell Signaling Technology, Inc. (Danvers, mA, 
USA). Species-specific HRP-labelled secondary antibodies 
were procured from Bio-Rad Laboratories (Hercules, CA, 
USA). Anticoagulated tubes were obtained from Greiener 
Bio-One (1 ml K3E K3EDTA; Frickenhausen, Germany) and 
a flat bottom 96-well micro-test plate were obtained from 
Tarsons (Kolkata, India). All other reagents were of analytical 
grade and milli-Q water was used for all the preparations.
Purification of Sclerotium rolfsii lectin (SRL). Purification of 
SRL from the sclerotial bodies was carried out as previously 
described (12). Briefly, SRL was extracted from powdered scle-
rotial bodies with 50 mm acetate buffer containing 100 mm 
NaCl (pH 4.3) and subjected to 30% methanol precipitation 
followed by ion exchange chromatography on Cm cellulose 
matrix and finally purified on a Superdex G-75 gel filtration 
column. The purified lectin was used for biodistribution and 
efficacy studies. The lectin activity was routinely determined 
by the 2-fold serial dilution method using trypsinised human 
erythrocytes.
Purification of polyclonal SRL antibodies from Protein A 
agarose column. Custom designed anti-SRL polyclonal 
antibodies were purified from immunized rabbit serum (from 
Bangalore Genei India) by subjecting to 50% ammonium 
sulphate precipitation, followed by affinity chromatography 
on a Protein A agarose column equilibrated with 100 mm 
phosphate buffer (pH 7.2) containing 150 mm NaCl phos-
phate-buffered saline (PBS). Bound SRL antibodies were 
eluted with 100 mm glycine-HCl (pH 2.5), dialysed against 
PBS and stored at -20˚C.
Cell culture. Human colon cancer HT29 cells were obtained 
from the European Cell Culture Collection via the Public 
Health Laboratory Service (Porton Down, UK). HT29 cells 
were cultured in DmEm supplemented with 10% FBS, 
100 units/ml penicillin and 100 µg/ml streptomycin (complete 
DMEM) at 37˚C in 5% CO2.
Mice. All animal experiments were carried out at the 
Advanced Centre for Treatment, Research and Education 
in Cancer with approval from the Ethics Committee (IRB 
approval no. 07/2012) of Tata memorial Centre-ACTREC-
IAEC (Institutional Animal Ethics Committee). Inbred female 
BALB/c nude mice (6-8 weeks old, weighing 18-22 g) for 
efficacy studies and male Swiss albino mice (6-8 weeks old, 
weighing 20-25 g) for pharmacokinetics and biodistribu-
tion studies were used. The animals were housed in groups 
of 4-5 per polycarbonate cage under individually ventilated 
caging systems (IvC's) under controlled conditions of 55±5% 
humidity, 22±2˚C temperature, and light cycle (12:12 h). All 
mice were provided with easy access to in-house pelleted feed 
and with ad libitum Uv-treated water and were monitored 
daily for general health status.
Efficacy studies of SRL on tumour growth in BALB/c nude 
mice. HT29 cells were suspended at 1x107 cells/ml in DmEm 
and a cell suspension (0.1 ml) was injected subcutaneously 
into two donor mice. After 4 weeks, the tumours from these 
donor mice were excised, chopped into 2- to 3-mm fragments 
and a single piece of tumour was transplanted subcutaneously 
into each of 12 BALB/c nude mice. Tumours were allowed to 
grow to reach the appropriate size of 5-6 mm, i.e. 80-120 mm3 
in volume and animals were divided randomly into 2 groups of 
5 mice in each group, one for SRL treatment (T) and other used 
as a control (TBS, C). mice were intraperitoneally adminis-
tered SRL (30 mg/kg body weight/mouse) in TBS (pH 7.5) on 
every other days for 17 days for a total of 9 doses. The mice in 
the control group were injected intraperitoneally with TBS at 
the same units (5-10 UI) and maintained for 2 weeks after the 
last dose. The mice were weighed and tumour volume was also 
determined by measuring the length (L) and width (W) of the 
tumour after each injection. The tumour volume at day n (Tvn) 
was calculated as Tv (mm3) = (L x W2)/2. The relative tumour 
volume at day n (RTvn) vs. day 0 was expressed according to 
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the formula: RTvn = Tvn/Tv0 (21,22). Regression of tumour 
T/C (%) in the treated vs. control mice was calculated using: 
T/C (%) = (mean RTv of treated/control group) x 100. The 
changes in the tumour size of the treated mice at different 
time-points compared to the control were used for monitoring 
the efficacy of the lectin. Mice were sacrificed 2 weeks after 
the last dose, and whole blood was collected in tubes coated 
with anticoagulant and used for analysis of total blood cell 
count, hemoglobin content, WBC and platelet count. Tumours 
were excised and organs such as liver, kidney and lung were 
collected directly in PBS to remove the blood traces, wrapped 
in aluminium foil and stored at -80˚C until further use for 
immunohistological analysis. Excised tumours were also snap 
frozen and stored at -80˚C for STR analysis.
PCR analysis of short tandem repeat (STR). In order to ascer-
tain the human origin of the tumours using short tandem 
repeat (STR) method (23), a small piece of the tumour tissues 
was collected from BALB/c mice with HT-29 xenograft, 
excised after 2 weeks from the last dose of injection. These 
tissues were snap frozen and stored at -80˚C for extraction of 
DNA. DNA was extracted from the samples using phenol 
chloroform extraction followed by ethanol precipitation. The 
DNA precipitates were suspended in Tris-EDTA (TE) buffer, 
pH 8.4. The extracted DNA was subjected to PCR amplifica-
tion using human-specific microsatellite primers (forward, 
5'-TGCCATTTGTGGGTACATTC-3' and reverse, 5'-TTG 
TGTTTCTTTTTCTGTTCCTACA-3'). In brief, 100 ng of 
target DNA was amplified in a 15-µl reaction volume 
containing 5 IU of Taq DNA polymerase, 0.4 pm each oligo-
nucleotide primer, 10 mm Tris buffer, 3.5 mm mgCl2, 0.4 mm 
each of dNTPs. PCR was performed with a 5-min denatur-
ation at 94˚C followed by 34 cycles of a 20-sec denaturation at 
94˚C, a 20-sec annealing at 58˚C, and a 30-sec elongation at 
72˚C in a thermal cycler (Eppendorf, Hauppauge, NY, USA). 
Amplicon was separated on 2% agarose gel and visualized by 
Uv light.
Pharmacokinetics and biodistribution studies. Swiss albino 
mice were randomized into two groups, the control group 
(TBS) and the SRL-treated group which included 4 time-
points (1, 6, 24 and 48 h) with 3 animals for each time-point. 
Lectin was prepared in TBS (pH 7.5), hence TBS served as 
the vehicle control. Animals were injected intraperitone-
ally with TBS and SRL (24 mg/kg body weight/mouse) and 
maintained for different time-points and blood was collected 
from the treated and control mice by retro-orbital bleeding. 
After incubation of the blood at room temperature (RT) for 
15 min, serum was collected by centrifuging the sample at 
2,500 rpm for 15 min at 4˚C and stored at -80˚C until further 
use. The pharmacokinetic profile of the serum samples was 
evaluated by ELISA. Serum samples collected at 24 h were 
also analysed for biochemical parameters of toxicity such 
as serum liver enzymes (aspartate transaminase and alanine 
transaminase), lactate dehydrogenase (LDH), blood urea 
nitrogen (BUN) and creatinine levels [carried out at Unique 
Bio Diagnostics Enterprises (mumbai, India)]. Animals were 
then sacrificed by cervical dislocation, and the organs (liver, 
kidney, heart, stomach, lungs, spleen, intestine and brain) were 
collected directly in PBS to remove the blood traces, wrapped 
in aluminium foil and stored at -80˚C until further use for 
biodistribution studies by ELISA or histology.
Tissue homogenization. Tissue homogenate was prepared by 
taking a part of the tissue from each organ, thawed on ice, 
weighed in a 2-ml Eppendorf tube and extracted in extraction 
buffer, PBS pH 7.4 (four volume/g of organ weight). Protease 
Inhibitor Cocktail Set III was added to the extraction buffer 
(1/20th volume of the tissue weight) and subjected to homog-
enization using an electric homogenizer (24,25). Prior to 
homogenization, the probe was dipped in ice and the tissue was 
homogenized at 4˚C with 8-10 oscillate up- and down-strokes 
for soft tissues derived from organs such as the liver, stomach, 
small intestine, lung, spleen, kidney and brain; whereas, hard 
tissues from the heart required more strokes and agitation. 
After homogenization, each sample was centrifuged for 
20 min at 16,000 rpm at 4˚C and the supernatant was collected 
and stored at -80˚C until further use for analysis.
Bioanalytical validation. A calibration curve was constructed 
using different concentrations of SRL (0.002-0.312 µg/ml and 
0.002-0.078 µg/ml) including a lower limit of quantification 
(LLOQ) for evaluating SRL in organ and serum extracts, 
respectively. Analytical recovery by ELISA was evaluated by 
adding serum and organ extracts at a 1:100 dilution and using 
the respective calibration curves and measuring its recovery 
using the same procedure and conditions as described in the 
ELISA experiments. The absorbance was measured at 450 nm 
and values were plotted against the concentrations. The 
LLOQ was set as the lowest measurable concentration with 
acceptable accuracy and precision not >20% of the expected 
values (26,27). Precision and accuracy were determined 
by analyzing quality control samples (QCs). Recovery was 
computed by comparing responses in triplicate of extracted 
QCs (28,29).
ELISA. Indirect ELISA was performed using 96-well plates. 
The plates were pre-coated with a known concentration of 
SRL (0.002-0.3 µg/100 µl/well), serum samples or tissue 
homogenate (1:100 dilution) in coating buffer (15 mm sodium 
carbonate and 17 mm bicarbonate buffer, pH 9.6, containing 
3 mM sodium azide) and incubated overnight at 4˚C. Wells 
were washed thrice with 50 mm PBS, at pH 7.4 containing 
0.1% (v/v) Tween-20 (PBST) to remove the unbound proteins. 
Non-specific binding was blocked by incubating with 100 µl 
of 1% BSA in PBS for 2 h at RT at 37˚C, followed by washing 
twice with PBST to remove excess blocking agent. Wells 
were incubated with rabbit anti-SRL polyclonal antibodies 
(100 µl/well, 1:10,000 dilutions in PBS) overnight at 4˚C. 
After washing, HRP-conjugated anti-rabbit IgG secondary 
antibodies (Sigma-Aldrich) at 1:10,000 dilutions were added 
and incubated for 2 h at RT at 37˚C. The colour was devel-
oped by the addition of 3,3',5,5'-tetramethylbenzidine (TmB; 
Sigma-Aldrich). The reaction was stopped using 4 m H2SO4 
(100 µl/well) and the absorbance was recorded at 450 nm on a 
microtiter plate reader (Tecan, Crailsheim, Germany).
Histological analysis. Histochemical examinations were 
performed using the tissue samples of the tumors and organs 
including liver, spleen, kidney, heart, lung, stomach, small 
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intestine and brain. Excised tumours were collected and fixed 
in 10% formalin and embedded in paraffin blocks, and 5-µm 
sections were used for hematoxylin and eosin (H&E) staining 
and for immunohistochemistry (IHC). The histological 
sections were observed under an optical microscope and 
photographed.
Immunohistochemical staining. Sections (5-µm thick) of the 
SRL-treated tumours with the controls were prepared by using 
the tumour tissues collected from the snap-frozen samples 
stored at -80˚C and stained with a specific mouse anti-CD31 
(PECAm-1) antibody (clone mEm-05) according to the 
manufacturer's instructions. The primary antibody (1:500) 
was diluted in PBS and incubated with samples at RT for 1 h 
followed by washing with TBST and then with HRP-conjugated 
goat anti-mouse IgG (H+L) secondary antibodies (1:3,000) 
diluted in PBS and incubated at RT for 1 h. Finally the slides 
were developed using 3,3'-diaminobenzidine (DAB) substrate 
and counterstained with hematoxylin. Images (magnification, 
x10) were captured to monitor CD31 expression.
Statistical analysis. The antitumor activity (as measured 
by differences in tumor mass) was expressed as mean ± 
standard deviation (SD). In vivo data and ELISA calibration 
curve with unknowns was analyzed using GraphPad Prism 6. 
The statistical significance of differences in tumor volume 
was determined by one-way analysis of variance (ANOvA), 
followed by Sidak test for three or more groups; a value of 
P<0.05 was considered as significant.
Results
SRL inhibits tumour growth in BALB/c nude mice bearing 
HT-29 xenografts. mice injected intraperitoneally with SRL 
(30 mg/kg body weight/mouse) showed significant inhibition 
(35.8%, P<0.0001) of tumour growth when compared with 
that observed in the control group (Fig. 1). The average initial 
tumour volume in the TBS and SRL-treated groups was 
155±4.7 and 147±10.9 mm3, respectively before tumour cell 
treatment and the average tumour volume after completion of 
9 doses was 353±71.2 and 171±16 mm3, respectively (P<0.001). 
No noticeable change in the weight and tumour volume of 
either control or treated group was observed after maintaining 
treatment for 14 days. The histology of the tumour sections of 
the SRL-treated and untreated animals showed marked differ-
ences. The SRL-treated mouse tumours appeared more like 
normal ones while the TBS-treated control mouse tumours 
showed a characteristic tumour appearance. The histology of 
liver sections showed that SRL-treated mice appeared normal 
compared to the control-treated mice bearing tumours, indi-
cating the tumour-regressing effect of SRL (Fig. 2). moreover, 
all the treated animals were healthy without any significant 
Figure 1. SRL inhibits tumour growth in mice bearing HT-29 xenografts. BALB/c nude mice bearing HT29 xenografts were injected intraperitoneally with 
TBS or SRL (30 mg/kg body weight), for a total of 9 doses and were monitored for 2 weeks after the last dose. (A) Graphical presentation of tumour volume 
(mm3) of control TBS-treated and SRL-treated mice following different doses showing significant tumour growth inhibition (*P<0.05, **P<0.01 and ***P<0.001). 
(B) Control-treated mouse with a tumour and SRL-treated mouse with clear tumour regression. (C) SRL-treated regressed tumour partially excised. (D) 
Excised tumour of an SRL-treated mouse with necrotic appearance and a tumour from a TBS-treated (control) mouse.
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changes in body weight compared to the controls. Complete 
blood count (CBC) revealed no detectable changes in the 
SRL-treated and TBS-treated groups (Table I). PCR analysis 
of the tumours obtained from the experimental mice showed 
similar product size of 275 bp as that of the implanted HT29 
cells, indicating that the tumours which developed in nude 
mice were from the implanted human cancer cells and not 
from the mice (Fig. 3).
Anti-angiogenic effect of SRL. SRL-treated animals also 
showed clear reduction in the number of blood vessels in the 
excised tumours compared with that from the control-treated 
Figure 2. Immunohistochemistry analysis. Tumour sections of SRL-treated and control-treated mice were sectioned and stained with (A) H&E and (B) anti-
CD31 antibody. (C) H&E-stained liver sections of SRL-treated and control-treated mice. Arrow indicates necrotic tumour.
Figure 3. PCR analyses of the tumours in the experimental xenograft animals. 
Small pieces of the viable tumour collected from BALB/c mice with HT-29 
xenografts after 9 doses of treatment, from the SRL-treated and control-
treated animals were analysed by PCR. Lane 1, marker; lane 2, blank; lanes 
3-5, mouse tail DNA as a negative control; and lanes 6-8, DNA from excised 
HT29 xenografts.
Table II. Toxicity studies of SRL in Swiss albino mice.
Parameters Std. values TBS SRL
OT IU/l 54-298 98.6 64.5
PT IU/l 17-77 43 25.5
CREAT mg/dl 0.3-1 0.43 0.4
BUN mg/dl 8-33 40.7 33.6
LDH g/dl 159-1045 1132.3 557.5
OT, aspartate aminotransferase; PT, alanine aminotransferase; CREAT, 
creatinine; BUN, blood urea nitrogen; LDH, lactate dehyrogenase.
Table I. Toxicity studies of SRL in BALB/c nude mice.
Parameters SRL (750 µg/mice) Control (TBS)
Initial body weight (g) 20.31 20.62
Final body weight (g) 19.97 20.94
mortality  None None
RBC (106/µl) 9.69 10.33
WBC (103/µl) 1.81 1.38
Platelet count (103/µl) 1009 990
Hemoglobin (g/dl) 14.4 15.73
RBC, red blood corpuscles; WBC, white blood corpuscles.
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animals (Fig. 1), indicating an effect of SRL treatment on 
suppression of angiogenesis. The anti-angiogenesis effect of 
SRL was also supported by the immunohistological analysis 
in which the expression of PECAm (CD31), an angiogenesis 
marker, was observed to be much lower in the SRL-treated 
animals than that in the control-treated animals (Fig. 2B).
Pharmacokinetic profile. Pharmacokinetic profile of SRL 
in Swiss albino mice was obtained by evaluation of serum 
samples from the SRL-treated mice by ELISA. mice injected 
with SRL (24 mg/kg body weight/mouse) intraperitone-
ally showed maximal SRL concentrations in serum at 24 h 
(8.02 µg/ml) (Fig. 4A). These results indicate that SRL was 
not accumulated in the body and was eliminated. Biochemical 
parameters in serum samples collected at 24 h and analysed 
for hepatic function namely SGPT, SGOT, bilirubin and 
cholesterol exhibited no significant alterations between the 
SRL-treated mice and control-treated mice. Biochemical 
Figure 4. Pharmacokinetics and biodistribution of SRL in mice. Swiss Albino mice were injected intraperitoneally with SRL (24 mg/kg body weight/mouse, 
n=3), and serum and tissue samples were collected at different time-points and analysed by ELISA. (A) Concentration of SRL (µg/ml) in serum at different 
time-points. (B) Biodistribution of SRL (µg/gm) in organs at different time-points.
Figure 5. Biodistribution of SRL in tissues. After SRL inoculation (24 mg/kg body weight/mouse) for 1, 6, 24 and 48 h, the mouse liver, spleen, kidney, lung, 
brain, stomach, small intestine and heart were removed and processed for sectioning and H&E staining. Representative images at 24 h are shown. 
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parameters related to kidney functions including urea, uric 
acid creatinine and total protein also showed no significant 
differences between the SRL-treated and control group 
(Table II). These results indicate the non-toxic nature of SRL 
treatment in the mice.
In vivo biodistribution. The presence of SRL in various organs 
including the liver, kidney, lung, spleen, stomach, small intes-
tine, heart and brain, respectively was analysed. The lectin 
was detected in trace amounts in the kidney but not in any 
other organ (Fig. 4B).  SRL at 76, 113, 79 and 22 µg/g was 
detected in the kidney at 1, 6, 24 and 48 h, respectively. H&E 
staining of tissue sections of the different organs showed no 
morphological changes at 24 h between the SRL-treated or 
control-treated animals (Fig. 5). These results suggest that 
SRL is effectively cleared in the body and is non-toxic to mice.
Discussion
The present study reports that when administered intraperito-
neally, SRL reduces tumour growth and inhibits angiogenesis 
in human colon cancer HT-29 cell xenografts in mice and is 
non-toxic. SRL was demonstrated to have good renal clear-
ance and was eliminated without causing any sign of toxicity 
or significant changes in biochemical parameters of the mice.
Previous studies have shown that SRL induces cell apoptosis 
and inhibits cell growth in human colon cancer cells in vitro and 
suppresses tumour growth in NOD-SCID mice bearing HT-29 
xenografts in vivo when injected intratumourally (16). SRL was 
shown to affect multiple signalling pathways in HT-29 cells 
by interacting with cell membrane proteins involved in cell 
survival, apoptosis and tumorigenesis (19,20).The present study 
revealed that intraperitoneal introduction of SRL suppressed 
tumour growth in the xenograft mouse model. H&E staining of 
the liver sections of the SRL-treated and control-treated mice 
showed no difference in morphology of the liver but the expres-
sion of CD-31 was substantially lower in the SRL-treated mice. 
This suggests that SRL treatment also inhibits angiogenesis. 
After SRL intraperitoneal injection, the level of SRL in the 
blood was seen to be peaked at 24 h. It is known that almost 
all drugs, chemicals and xenobiotics are eliminated through 
renal excretion; hence it was necessary to estimate the effects 
of SRL on kidney function (30,31). There were no changes in 
biochemical parameters in the SRL-treated mice compared to 
the control-treated mice group indicating no alterations in the 
animal hepatic and renal functions. Biodistribution analysis 
showed that SRL did not accumulated in any organ apart from 
its temporary appearance in the kidney. Pharmacokinetic and 
biodistribution patterns indicate that SRL has a very fast rate of 
absorption and is rapidly distributed to the entire body through 
the circulation. SRL appears to be quickly eliminated from the 
body through the kidney, indicating a beneficial property of 
SRL as a therapeutic agent.
SRL binds to the oncofetal TF antigen and TF-related 
carbohydrate structures (12,13). In colorectal cancer, 
increased expression of oncofetal TF and sialylated Tn is 
common (32-37) and can be detected using lectins including 
peanut lectin, Arachis hypogea (PNA) (38) and Sambucus 
nigra lectin (SNA). many lectins have shown anticancer 
effects when tested in vitro and in some cases also in vivo 
but not many have reached clinical trials partly due to their 
cytotoxicity (39). Tn antigen (GalNAc-Ser/Thr)-binding 
Helix pomatia lectin (HPA) identifies a subset of metastatic 
colorectal cancer. HPA binding also reveals overexpression of 
sialyl-Lewis X carbohydrate antigen which is correlated with 
poor prognosis of colorectal cancer (40,41). Viscum album 
var. coloratum agglutinin (vCA), binding lectin from Korean 
mistletoe has been used in human clinical trials at low doses for 
the treatment of different cancers without serious side-effects 
and the action seems to be beneficial (39). A mannose/sialic 
acid-binding plant lectin from Polygonatum cyrtonema lectin 
(PCL) has shown antitumour effects by inducing apoptosis 
and autophagy in cancer cells (42,43). Two cytotoxic mistletoe 
isolectins designated as KmL-IIU and KmL-IIL were found 
to exhibit cytotoxicity in various human and mouse cancer cell 
lines (44). mistletoe lectin has been extensively studied for its 
clinical use and has reached clinical trials (45,46). Reports 
are available on the antitumor effects of Concanavalin A 
lectin, one of the most extensively studied lectin. Clinical use 
of Con A is questionable due to its strong cytotoxic effects 
including the induction of hepatitis (47,48).
The strong anti-proliferative, antitumour and anti-angio-
genesis effects of SRL shown in vitro and in vivo in the present 
and previous studies with no detectable cytotoxic effects 
confirm the high potential of SRL as a therapeutic agent for 
cancer treatment.
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